AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-18T20:00:00Z
TAK or CTLT: Which Is the Better Value Stock Right Now?
Thu 03 Oct 24, 03:40 PMIs Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
Thu 03 Oct 24, 01:40 PMTempus Stock Up Following Collaboration Expansion in Oncology R&D
Mon 30 Sep 24, 03:20 PMHow Many Stocks Should You Own?
Fri 27 Sep 24, 10:08 PMThe Zacks Analyst Blog Highlights Takeda Pharma, Naspers and Packaging Corp. of America
Tue 24 Sep 24, 12:58 PMHUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
Tue 24 Sep 24, 07:00 AMTakeda Pharmaceutical Company Limited (TAK): Hedge Funds Are Bullish On This Japanese Stock Now
Sun 22 Sep 24, 07:55 AM| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | 375090.00M | 302571.00M | 366235.00M | -60754.00000M | 94896.00M |
| Minority interest | -21.00000M | -107.00000M | 4140.00M | 4003.00M | 4006.00M |
| Net income | 317017.00M | 230059.00M | 376005.00M | 44241.00M | 109126.00M |
| Selling general administrative | 997309.00M | 886361.00M | 875663.00M | 964737.00M | 717599.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 2783406.00M | 2462160.00M | 2203504.00M | 2201424.00M | 1437534.00M |
| Reconciled depreciation | 664400.00M | 583151.00M | 559671.00M | 583649.00M | 272446.00M |
| Ebit | 544788.00M | 469178.00M | 614866.00M | 104252.00M | 103937.00M |
| Ebitda | 1209188.00M | 1052329.00M | 1174537.00M | 687901.00M | 376383.00M |
| Depreciation and amortization | 664400.00M | 583151.00M | 559671.00M | 583649.00M | 272446.00M |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 490505.00M | 460844.00M | 509269.00M | 100408.00M | 204969.00M |
| Other operating expenses | 3536972.00M | 3108161.00M | 2688543.00M | 3190780.00M | 1936859.00M |
| Interest expense | 169698.00M | 166607.00M | 248631.00M | 165006.00M | 48158.00M |
| Tax provision | 58052.00M | 72405.00M | -9936.00000M | -105044.00000M | -14118.00000M |
| Interest income | 62913.00M | 23700.00M | 105521.00M | 11202.00M | 6619.00M |
| Net interest income | -106785.00000M | -142907.00000M | -143110.00000M | -146649.00000M | -60959.00000M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 58052.00M | 72405.00M | -9936.00000M | -105044.00000M | -14118.00000M |
| Total revenue | 4027478.00M | 3569006.00M | 3197812.00M | 3291188.00M | 2097224.00M |
| Total operating expenses | 2292900.00M | 2001315.00M | 1694235.00M | 2101016.00M | 1277169.00M |
| Cost of revenue | 1244072.00M | 1106846.00M | 994308.00M | 1089764.00M | 659690.00M |
| Total other income expense net | -8630.00000M | -15367.00000M | 76.00M | -23987.00000M | -4510.00000M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 317038.00M | 230166.00M | 376171.00M | 44290.00M | 109014.00M |
| Net income applicable to common shares | - | 230059.00M | 376005.00M | 44241.00M | 135192.00M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 13957750.00M | 13178018.00M | 12912293.00M | 12821094.00M | 13872322.00M |
| Intangible assets | 4269657.00M | 3818544.00M | 3909106.00M | 4171361.00M | 4860368.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 160867.00M | 141098.00M | 122789.00M | 114196.00M | 109666.00M |
| Total liab | 7603079.00M | 7494495.00M | 7735116.00M | 8093608.00M | 8708734.00M |
| Total stockholder equity | 6354122.00M | 5683019.00M | 5173037.00M | 4723483.00M | 5159582.00M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 1493107.00M | 1425440.00M | 1407185.00M | 1270265.00M | 1313637.00M |
| Common stock | 1676345.00M | 1676263.00M | 1668145.00M | 1668123.00M | 1643585.00M |
| Capital stock | 1676345.00M | 1676263.00M | 1668145.00M | 1668123.00M | 1643585.00M |
| Retained earnings | 1541146.00M | 1479716.00M | 1509906.00M | 1369972.00M | 1569365.00M |
| Other liab | 544129.00M | 795986.00M | 962497.00M | 1082848.00M | 1110462.00M |
| Good will | 4790723.00M | 4407749.00M | 4033917.00M | 4012528.00M | 4161403.00M |
| Other assets | 709011.00M | 678704.00M | 689992.00M | 674069.00M | 368200.00M |
| Cash | 533530.00M | 849695.00M | 966222.00M | 637614.00M | 702093.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2481940.00M | 2145730.00M | 1773176.00M | 2175898.00M | 2510931.00M |
| Current deferred revenue | 740737.00M | 644420.00M | 616481.00M | 587983.00M | 627264.00M |
| Net debt | 3848811.00M | 3495716.00M | 3669149.00M | 4455690.00M | 5048858.00M |
| Short term debt | 339600.00M | 203993.00M | 22153.00M | 586817.00M | 984946.00M |
| Short long term debt | 339600.00M | 203993.00M | 22153.00M | 586817.00M | 984946.00M |
| Short long term debt total | 4382341.00M | 4345411.00M | 4635371.00M | 5093304.00M | 5750951.00M |
| Other stockholder equity | 3136631.00M | 2527040.00M | 1994986.00M | 1685388.00M | 1946632.00M |
| Property plant equipment | - | 1582800.00M | 1453917.00M | 1386370.00M | 1331931.00M |
| Total current assets | 2397956.00M | 2593642.00M | 2712893.00M | 2469432.00M | 3050658.00M |
| Long term investments | 378857.00M | 330133.00M | 348350.00M | 369455.00M | 306899.00M |
| Net tangible assets | - | -2543274.00000M | -2769986.00000M | -3460406.00000M | -3809435.00000M |
| Short term investments | 20174.00M | 25305.00M | 36598.00M | 15822.00M | 23276.00M |
| Net receivables | 681693.00M | 724377.00M | 812714.00M | 784921.00M | 749119.00M |
| Long term debt | 4042741.00M | 4141418.00M | 4613218.00M | 4506487.00M | 4766005.00M |
| Inventory | 986457.00M | 853167.00M | 753881.00M | 759599.00M | 986744.00M |
| Accounts payable | 649233.00M | 516297.00M | 343838.00M | 318816.00M | 212348.00M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | - | - | - | - | 0.00000M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | - | 0.00000M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 63325.00M | 82611.00M | 100341.00M | 103846.00M | 87472.00M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 11559794.00M | 10584376.00M | 10199400.00M | 10351662.00M | 10821664.00M |
| Capital lease obligations | - | - | - | - | 0.00000M |
| Long term debt total | - | - | - | - | 0.00000M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -607102.00000M | 8580.00M | 62008.00M | 41851.00M | 47936.00M |
| Change to liabilities | 0.00000M | 125157.00M | 36620.00M | -29932.00000M | -16413.00000M |
| Total cashflows from investing activities | - | -198125.00000M | 393530.00M | 292119.00M | -2835698.00000M |
| Net borrowings | -285071.00000M | -600477.00000M | -660504.00000M | -586090.00000M | 3161504.00M |
| Total cash from financing activities | -709148.00000M | -1070265.00000M | -1088354.00000M | -1005213.00000M | 2946237.00M |
| Change to operating activities | 63568.00M | -66289.00000M | 260285.00M | 44458.00M | -26284.00000M |
| Net income | 317038.00M | 230166.00M | 376171.00M | 44290.00M | 109014.00M |
| Change in cash | -316165.00000M | -116527.00000M | 328608.00M | -65108.00000M | 407120.00M |
| Begin period cash flow | 849695.00M | 966222.00M | 637614.00M | 702722.00M | 294973.00M |
| End period cash flow | 533530.00M | 849695.00M | 966222.00M | 637614.00M | 702093.00M |
| Total cash from operating activities | 977156.00M | 1123105.00M | 1010931.00M | 669752.00M | 328479.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 664400.00M | 583151.00M | 559671.00M | 583649.00M | 272446.00M |
| Other cashflows from investing activities | 5564.00M | -1007.00000M | -8851.00000M | -1256.00000M | 73318.00M |
| Dividends paid | -279416.00000M | -283665.00000M | -283357.00000M | -282582.00000M | 142952.00M |
| Change to inventory | -79155.00000M | -46148.00000M | 25978.00M | 137492.00M | 58678.00M |
| Change to account receivables | - | 127294.00M | -9316.00000M | -34826.00000M | -13382.00000M |
| Sale purchase of stock | -26929.00000M | -77531.00000M | -2141.00000M | -3737.00000M | -1172.00000M |
| Other cashflows from financing activities | -2732.00000M | 140742.00M | 1037163.00M | 12163.00M | 3092102.00M |
| Change to netincome | 21003.00M | 169881.00M | -238312.00000M | -75330.00000M | -49042.00000M |
| Capital expenditures | 633689.00M | 186037.00M | 236468.00M | 217710.00M | 134114.00M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | -25264.00000M | 98605.00M | 275781.00M | 94672.00M | 75946.00M |
| Stock based compensation | 60672.00M | 43374.00M | 37663.00M | 29122.00M | 20084.00M |
| Other non cash items | -97742.00000M | 95404.00M | -228419.00000M | 23063.00M | -134893.00000M |
| Free cash flow | 343467.00M | 937068.00M | 774463.00M | 452042.00M | 194365.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% | 25.38 | 32.60 | 11.59 | 0.01 | 0.88 | 0.02 | 0.07 |
| ZTS Zoetis Inc |
-2.975 1.78% | 164.03 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.12 0.42% | 28.66 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-1.925 1.33% | 142.50 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.07 0.53% | 13.04 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668
| Name | Title | Year Born |
|---|---|---|
| Mr. Christophe Weber | Pres, CEO & Representative Director | 1966 |
| Mr. Constantine Saroukos | CFO & Representative Director | 1971 |
| Dr. Andrew S. Plump | Pres of R&D and Representative Director | 1965 |
| Dr. Seigo Izumo | Chair of Management Board | NA |
| Mr. Haruhiko Hirate | Member of Management Board | 1957 |
| Salvatore Alesci | Member of Management Board and Head of R&D Global Science & Biomedical Policy | NA |
| Norimasa Takeda | Chief Accounting Officer & Corp. Controller | NA |
| Mr. Iwaaki Taniguchi | Sr. VP of Corp. Fin. & Controlling Department | NA |
| Mr. Gabriele Ricci | Chief Data & Technology Officer | 1978 |
| Mr. Christopher David O'Reilly | Global Head of Investor Relations & Global Fin. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...